复发性肺癌质子束再照射患者临床结局:质子协作组与佛罗里达大学质子治疗研究所前瞻性登记研究
本研究基于2项前瞻性登记研究,评估79例复发性肺癌患者接受质子束再照射的临床结局与毒性。中位随访10.7个月,中位总生存15.2个月、无进展生存10.5个月,急性与晚期3级毒性分别为6%和1%。多因素分析显示ECOG体能状态≤1与总生存和无进展生存相关。
要点
- 79例复发性肺癌患者接受质子束再照射,中位总生存15.2个月、无进展生存10.5个月。
- 急性3级毒性发生率6%,晚期3级毒性1%,3例患者死于可能的放射性毒性。
- 多因素分析显示ECOG体能状态≤1与总生存(HR 0.35)和无进展生存(HR 0.32)相关。
核心结论
- 这是迄今规模最大的复发性肺癌质子束再照射系列,提示质子束再照射耐受性良好,毒性可接受且疗效令人鼓舞。
- ECOG体能状态与总生存和无进展生存相关。
研究设计与样本
- 研究纳入2项前瞻性登记试验中在8家机构连续接受质子束再照射的79例复发性肺癌患者。
- 既往肺癌放疗采用常规分割者占68%(中位EQD2 60.2 Gy),采用大分割/立体定向体部放疗者占32%(中位EQD2 83.3 Gy)。
- 9例(11%)在质子束治疗前接受过≥2程胸部照射,ECOG体能状态2-3分者占13%,既往放疗至质子束治疗的中位时间为19.9个月。
- 质子束治疗采用常规分割者占58%(中位EQD2 60 Gy),超分割者占3%(中位EQD2 62.7 Gy),大分割者占39%(中位EQD2 60.4 Gy);24例(30%)同步接受化疗。
主要发现
- 所有患者均按计划完成质子束治疗;质子束治疗后中位随访10.7个月,中位总生存15.2个月,中位无进展生存10.5个月。
- 急性3级毒性发生率为6%,晚期3级毒性发生率为1%;3例患者在质子束治疗后死于可能的放射性毒性。
- 多因素分析显示ECOG体能状态≤1与总生存相关(HR 0.35,95%CI 0.15-0.80,P=0.014),与无进展生存相关(HR 0.32,95%CI 0.14-0.73,P=0.007)。
临床怎么用
- 原文结论指出质子束再照射耐受性良好、毒性可接受且疗效令人鼓舞,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to assess clinical outcomes and toxicities of patients with recurrent lung cancer reirradiated with proton beam therapy (PBT) who were enrolled in 2 prospective registry trials. METHODS AND MATERIALS: Seventy-nine consecutive patients were reirradiated with PBT at 8 institutions. Conventionally fractionated radiation therapy was used to treat the previous lung cancer in 68% of patients (median equivalent dose in 2 Gy fractions [EQD2], 60.2 Gy) and hypofractionated/stereotactic body radiation therapy in 32% (median EQD2, 83.3 Gy). Nine patients (11%) received ≥2 courses of thoracic irradiation before PBT. Eastern Cooperative Oncology Group (ECOG) performance status was 2 to 3 in 13%. Median time from prior radiation therapy to PBT was 19.9 months. PBT was delivered with conventional fractionation in 58% (median EQD2, 60 Gy), hyperfractionation in 3% (median EQD2, 62.7 Gy), and hypofractionation in 39% (median EQD2, 60.4 Gy). Twenty-four patients (30%) received chemotherapy concurrently with PBT. RESULTS: All patients completed PBT as planned. At a median follow-up of 10.7 months after PBT, median overall survival (OS) and progression-free survival (PFS) were 15.2 months and 10.5 months, respectively. Acute and late grade 3 toxicities occurred in 6% and 1%, respectively. Three patients died after PBT from possible radiation toxicity. On multivariate analysis, ECOG performance status ≤1 was associated with OS (hazard ratio, 0.35; 95% confidence interval, 0.15-0.80; P = .014) and PFS (hazard ratio, 0.32; 95% confidence interval, 0.14-0.73; P = .007). CONCLUSIONS: This is the largest series to date of PBT reirradiation for recurrent lung cancer and indicates that reirradiation with PBT is well tolerated with acceptable toxicity and encouraging efficacy. ECOG performance status was associated with OS and PFS.
引用
- Badiyan SN, Rutenberg MS, Hoppe BS, et al. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Pract Radiat Oncol. 2019. PMID: 30802618. doi:10.1016/j.prro.2019.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。